Parallel to the increased sales of e-cigarettes and HTPs since the COVID-19 pandemic began, advertisements promoting the health benefits of e-cigarettes and HTPs as an alternative to traditional cigarettes have also increased 14,15
Among all tobacco and nicotine categories, nicotine pouches continue to demonstrate the strongest growth momentum
Last fall FDA Commissioner Margaret Hamburg claimed "flavored cigarettes are a gateway for many children and young adults to become regular smokers." In the same press release, Assistant Secretary of Health and Human Services Howard Koh made an even bolder assertion, implying that the ban will stop all underage smoking: Flavored cigarettes attract and allure kids into lifetime addiction
That's enough to warm any fan's heart
Potential therapies for EMT in COPD At present, bronchodilators (short-acting Beta2-agonists (SABA) and long-acting Beta2-agonists (LABA)), antimuscarinic drugs (short-acting antimuscarinics (SAMAs), and Long-acting muscarinic antagonists (LAMAs)), methylxanthines (Theophylline), anti-inflammatory agents, Inhaled corticosteroids (ICS), antibiotics, mucolytic (mucokinetics and dmucoregulators), antioxidant agents ( N -acetylcysteine, carbocysteine, and erdosteine) and Phosphodiesterase-4 (PDE4) inhibitors are commonly used drugs for the treatment of COPD [1]
